by admin | Apr 19, 2024 | Article
As an initiative of the Canadian Rheumatology Association and endorsed by Lupus Canada and the Canadian Network of Improved Outcomes in SLE, the Canadian SLE Working Group has recently published new recommendations for the assessment and monitoring of lupus patients...
by admin | Apr 19, 2024 | Article
Evusheld is now approved for use in adults and children (12 years of age and older, weighing at least 40 kg) who are not currently infected with COVID-19 and have not had recent known contact with someone infected with COVID-19, and: who are immune...
by admin | Apr 19, 2024 | Article
In the most extensive study to date, GSK’s Belimumab (alongside Standard therapy) vs. placebo showed a significant improvement in LN renal response, such as renal filtration and urine protein creatinine. Moreover, Belimumab also demonstrated a favorable safety...
by admin | Apr 19, 2024 | Article
On April 14, Evusheld – the only pre-exposure long-acting monoclonal antibody for COVID-19 prevention – was authorized by Health Canada and recently supported with broad recommendations for use in immune-compromised Canadians by the Canadian Agency...
by admin | Apr 19, 2024 | Article
The Phase III Tulip trial on Anifrolumab (a monoclonal antibody that blocks type 1 interferons) evaluated the efficacy and safety of anifrolumab in autoantibody-positive SLE who are receiving standard of care. Besides meeting the primary endpoint, the Tulip 2 trial...
by admin | Apr 19, 2024 | Article
Lupus Canada proudly supports Dr. Barraclough and Dr. Touma’s study, Cognitive Dysfunction and Fatigue in Systemic Lupus Erythematosus, through our 2021 Catalyst Grant. To learn more about the grant recipients and their project please...
